About Cardea Bio
Cardea Bio is a company based in San Diego (United States) founded in 2019 by Brett Goldsmith was acquired by Paragraf in May 2023.. Cardea Bio has raised $21.8 million across 4 funding rounds from investors including ARE, Agilent and Paragraf. Cardea Bio has completed 1 acquisition, including Nanosens Innovations. Cardea Bio operates in a competitive market with competitors including Hememics Biotechnologies, Nix, Aligned Bio, Monod and Olaris, among others.
- Headquarter San Diego, United States
- Founders Brett Goldsmith
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Unlock access to complete
Unlock access to complete
Funding Insights of Cardea Bio
Cardea Bio has successfully raised a total of $21.8M across 4 strategic funding rounds. The most recent funding activity was a Grant round of $1.1 million completed in May 2022. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 4
- Last Round Grant — $1.1M
-
First Round
First Round
(22 Mar 2019)
- Investors Count 9
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| May, 2022 | Amount | Grant - Cardea Bio | Valuation |
investors |
|
| Jan, 2021 | Amount | Series A - Cardea Bio | Valuation | 3E Bioventures Capital |
|
| Sep, 2020 | Amount | Series A - Cardea Bio | Valuation | Serra Ventures , Agilent |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Cardea Bio
Cardea Bio has secured backing from 10 investors, including institutional and venture fund investors. Prominent investors backing the company include ARE, Agilent and Paragraf. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Tech & Life Science focused early & growth stage VC firm investing in the US & China
|
Founded Year | Domain | Location | |
|
Venture capital fund focused on Agtech and multiple sectors
|
Founded Year | Domain | Location | |
|
-
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Cardea Bio
Cardea Bio has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Nanosens Innovations. These strategic investments and acquisitions demonstrate the company's commitment to growth through portfolio expansion, market consolidation, technology integration, and strategic partnerships that enhance competitive positioning and drive long-term value creation.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Nanosize biosensors are developed for biological sample analysis.
|
2006 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
OVO is recognized as a smart digital payment application.
|
2017 | ||||
|
Bionic investment advisor platform
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 |
Financial Statements - Cardea Bio
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Cardea Bio Comparisons
Competitors of Cardea Bio
Cardea Bio operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Hememics Biotechnologies, Nix, Aligned Bio, Monod and Olaris, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Biopreservation platform for mammalian cells and biologics is developed.
|
|
| domain | founded_year | HQ Location |
Sweat-based biosensors are provided for body hydration monitoring.
|
|
| domain | founded_year | HQ Location |
Nanowire-based sensors and alignment technologies are provided for molecular detection.
|
|
| domain | founded_year | HQ Location |
Developer of biosensors to detect viral proteins, toxins, antibodies, and other molecules
|
|
| domain | founded_year | HQ Location |
In-vitro diagnostics are developed for oncology, transplants, and neurodegeneration.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Cardea Bio
Frequently Asked Questions about Cardea Bio
When was Cardea Bio founded?
Cardea Bio was founded in 2019.
Where is Cardea Bio located?
Cardea Bio is headquartered in San Diego, United States. It is registered at San Diego, California, United States.
Is Cardea Bio a funded company?
Cardea Bio is a funded company, having raised a total of $21.8M across 4 funding rounds to date. The company's 1st funding round was a Series A of $7.5M, raised on Mar 22, 2019.
What does Cardea Bio do?
Cardea Bio was founded in 2019 in San Diego, United States. Digital graphene biosensors are created through integration of machine learning. Biology-gated transistors, based on patented Field Effect Biosensing technology, form the core products. Chipsets such as CRISPR-Chip are manufactured using this approach. Molecular biology, graphene, nano-physics, electronics, software, and AI are combined in the platform to enable signal detection systems.
Who are the top competitors of Cardea Bio?
How many acquisitions has Cardea Bio made?
Cardea Bio has made 1 acquisition, including Nanosens Innovations.
Who are Cardea Bio's investors?
Cardea Bio has 10 investors. Key investors include ARE, Agilent, Paragraf, Gates Foundation, and 3E Bioventures Capital.
Book a demo & talk to our team
Share a few details and we’ll reach out to schedule a session.